­­­Isofol appoints Gustaf Albèrt as Chief Financial Officer

Isofol Medical AB (publ) has recruited Gustaf Albèrt as Chief Financial Officer. With extensive experience from leading financial positions, Albèrt will strenghten Isofol Medical’s management team in the execution of the company’s development program of the drug candidate Modufolin®.

Isofol Medical AB (publ), a clinical stage oncology company, announces the appointment of Gustaf Albèrt as CFO effective as of the 1st of November. Gustaf Albèrt will have an important role in the continued development of Isofol focusing on the pivotal trial ISO-CC-007 where the company’s drug candidate Modufolin® will be evaluated as a first-line treatment for metastatic colorectal cancer.

Gustaf Albèrt joins Isofol from a previous position as the CEO of Elanders Sverige AB, a subsidiary of Elanders AB listed at Nasdaq Stockholm Mid Cap. Prior to his employment at Elanders, Albèrt worked for Deloitte as an authorized auditor, where he coordinated major Swedish and international audit assignments.

Anders Rabbe, CEO of Isofol, says “With the recruitment of Gustaf Albèrt to the position as CFO, the company’s management team is now well-assembled to effectively implement and carry out the company’s registration program with Modufolin®. With his experience and personal drive, Gustaf will have an important role in the continued development of Isofol. With an intense and exciting year in front of us, it is with great pleasure I welcome Gustaf to Isofol

For more information, please contact:

Anders Rabbe, CEO, Isofol Medical AB

E­mail: anders.rabbe@isofolmedical.com

Phone: +46 (0)707 646 500

About Modufolin®

Modufolin® (active ingredient [6R]-5,10-methylenetetrahydrofolate), is a novel folate-based compound developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. As Modufolin® does not require metabolic activation to exert its effect, Modufolin® is suitable for all patients irrespective of their capacity to activate folates. Modufolin® is currently being evaluated in a clinical Phase II study.

About Isofol Medical AB

Isofol Medical AB is a clinical stage oncology company developing Modufolin® as a first-line treatment of metastatic colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma. Through a worldwide exclusive license agreement, Isofol Medical holds the rights to commercialise Modufolin® with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the Nasdaq First North Premier. Certified Adviser is FNCA Sweden AB.


The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CET on 3 Oktober 2017.

Scroll to Top